Mackenzie Financial Increased Holdings in Acadia Pharmaceuticals

Summary

Mackenzie Financial Corporation increased its holdings in Acadia Pharmaceuticals by 180.1% during the fourth quarter, purchasing an additional 32,833 shares, bringing its total holdings to 51,065 shares valued at $937,000. Other institutional investors have also increased their positions. Acadia’s stock is currently down 3.1%, with a market cap of $3.62 billion and a P/E ratio of 27.69. Analysts have set price targets ranging from $24.00 to $32.00, with several maintaining ‘outperform’ or ‘buy’ ratings.Market Beat

Impact Analysis

This event is primarily at the company level, as it concerns Mackenzie Financial Corporation’s increased stake in Acadia Pharmaceuticals. The direct impact is an increase in institutional ownership, which can signal confidence in the company’s prospects to other investors. Despite the stock’s recent 3.1% decline, the increased holdings and positive analyst ratings (‘outperform’ or ‘buy’) suggest potential for future appreciation. The stock’s P/E ratio of 27.69 and market cap of $3.62 billion highlight its valuation metrics. Additionally, analysts’ target prices ranging from $24.00 to $32.00 provide a potential upside for the stock.Market Beat+ 3